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Abstract
Background: There is evidence from animal and in vitro models of the protective effects of caffeine in Alzheimer’s disease. The suggested mechanisms through 
which caffeine may protect neurons against Alzheimer’s disease pathology include the facilitation of beta-amyloid clearance, upregulation of cholinergic trans-
mission, and increased neuronal plasticity and survival. Epidemiological studies support that Alzheimer’s disease patients consume smaller amounts of coffee 
beverages throughout their lives as compared to age-matched cognitively healthy individuals. Objective: The aim of the present study was to determine whether 
the negative association between Alzheimer’s disease and coffee consumption may be influenced by a common genetic predisposition, given the fact that the 
pattern of coffee consumption is determined by both environmental and genetic factors. Method: We conducted an in silico search addressing the association 
between genetic polymorphisms related to coffee consumption and the diagnosis of Alzheimer’s disease. We further investigated the interactions between genes 
located in regions bearing these polymorphisms. Results: Our analysis revealed no evidence for a genetic association (nor interaction between related proteins) 
involving coffee consumption and Alzheimer’s disease. Discussion: The negative association between Alzheimer’s disease and coffee consumption suggested by 
epidemiological studies is most likely due to environmental factors that are not necessarily regulated by genetic background.
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Introduction
More than 90% of new therapeutics developed for Alzheimer’s disease 
(AD) have been unsuccessful1. The lack of an effective treatment con-
tributed to increase the attention to life style and dietary interventions 
that could modify the etiology of the disease2. Epidemiological studies 
have indicated a negative association between coffee consumption 
and AD, suggesting that caffeine may have neuroprotective effects 
against cognitive decline2-5. This xanthine-derived substance, highly 
concentrated in coffee, is a stimulant to the central nervous system 
that may be beneficial against certain deficits associated with AD3,6,7. 
Putative mechanisms for caffeine neuroprotection in AD include 
the facilitation of beta-amyloid clearance7,8, and the upregulation of 
cholinergic neurotransmission9 and/or signalling pathways related to 
neuronal plasticity and survival10-12. Most of those effects are probably 
mediated the stimulation of adenosine receptors13. However, evidence 
of beneficial effects of caffeine in human cognition is largely derived 
from epidemiological associations, with scarce direct evidence for 
the protective effects of coffee/caffeine in patients with AD14. Coffee 
consumption is determined by both environmental and genetic fac-
tors. Environmental factors related to coffee consumption include 
mainly age and sex, but it is also influenced by geographical location, 
religious preferences and socioeconomic conditions. Great effort 
has been made to identify genetic factors involved in coffee intake. 
Meta-analyses of genome-wide association indicated some com-
mon genetic variants that influence coffee consumption, localized 
in CYP1A1/CYP1A2, NRCAM and AHR genes15-17. AD is a multi-
factorial neurodegenerative disorder resulting from the interaction 
between multiple genetic and environmental factors18-20. Since there 
are genetic factors associated with both AD and coffee consumption, 
one cannot rule out the possibility that the negative association 
observed in epidemiological studies are due to a common genetic 
background, or even interactions among related gene products. In 
the present study, our aim was to evaluate genetic associations of 
single nucleotide polymorphisms (SNP) related to coffee consump-
tion in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
cohort, comprising patients with AD or mild cognitive impairment 
(MCI) and healthy age-matched controls. Also to investigate possible 
interactions among the products of genes associated with AD and 
those located near the coffee consumption SNP.
Methods
Sample 
Data used in the preparation of this article were obtained from 
the ADNI database (adni.loni.ucla.edu). The ADNI was launched 
in 2003 by the National Institute on Aging (NIA), the National 
Institute of Biomedical Imaging and Bioengineering (NIBIB), the 
Food and Drug Administration (FDA), private pharmaceutical 
companies and non-profit organizations, as a $60 million, 5-year 
public-private partnership. The primary goal of ADNI has been to 
test whether serial magnetic resonance imaging (MRI), positron 
emission tomography (PET), other biological markers, and clinical 
and neuropsychological assessment can be combined to measure 
the progression of MCI and early AD. Determination of sensitive 
and specific markers of very early AD progression is intended 
to aid researchers and clinicians to develop new treatments and 
monitor their effectiveness, as well as lessen the time and cost of 
clinical trials. 
The Principal Investigator of this initiative is Michael W. Weiner, 
MD, VA Medical Center and University of California – San Francisco. 
ADNI is the result of efforts of many co-investigators from a broad 
range of academic institutions and private corporations, and subjects 
have been recruited from over 50 sites across the U.S. and Canada. 
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The initial goal of ADNI was to recruit 800 subjects but ADNI has 
been followed by ADNI-GO and ADNI-2. To date these three pro-
tocols have recruited over 1,500 adults, ages 55 to 90, to participate 
in the research, consisting of cognitively normal older individuals, 
people with early or late MCI, and people with early AD. The follow 
up duration of each group is specified in the protocols for ADNI-1, 
ADNI-2 and ADNI-GO. Subjects originally recruited for ADNI-1 
and ADNI-GO had the option to be followed in ADNI-2. For up-
to-date information, see www.adni-info.org.
A total of 757 individuals were genotyped using the Illumina 
Human Genome 610 Quad BeadChips in the ADNI database down-
loaded in November 2011. We excluded individuals with less than 
65 years of age, since they might correspond to the early onset forms 
of AD. The most recent clinical data of those subjects, at the time, 
revealed 198 healthy controls (CT), 193 classified as MCI and 318 
diagnosed with AD. All those individuals had less than 10% missing 
genotypes. There was no information regarding coffee consumption 
in the ADNI database at the time of download.
Genotype data of SNPs that had been strongly associated 
with coffee consumption15-17 was retrieved from the ADNI data-
base. From the chosen SNPs (rs12148488, rs2470893, rs2472297, 
rs2472304, rs382140, rs4410790, rs5751876, rs6495122, rs762551), 
only rs5751876 was not present in the ADNI database. The remain-
ing SNPs passed our quality control with a call rate above 90% and 
minor allele frequency greater than 2%. rs16868941 was in Hardy 
Weinberg disequilibrium (p < 0.10; table 1) and was excluded from 
further analysis. Quality control analysis was performed with PLINK 
v1.07 and R software.
Firstly, we compared the genome location of the coffee consump-
tion and AD SNPs from the top 10 associated SNPs in the repository 
of meta-analyses AlzGene (last updated 18th April 2011 – http://
www.alzgene.org)21.
We used the Search Tool for the Retrieval of Interacting Genes/
Proteins (STRING; http://string-db.org)22 to investigate known 
protein interactions and pathway enrichment among the coffee 
consumption genes (up to 50 kb of distance, if the SNP is not inside 
a gene) and the top 10 AD associated genes from Alzgene21. Sig-
nificance for this analysis was set as p < 0.05 after FDR correction.
APOE alleles frequencies were retrieved from AlzGene meta-
analysis and ADNI database. We used a chi-square test in LibreOffice 
Calc 3.5 (significance, p < 0.05) to compare the frequencies in control 
and AD individuals in those sets.
Association of each caffeine SNP among controls, MCI or AD was 
tested with Wald test for multinomial logistic regression controlled 
by age, gender, years of education and presence of the e4 allele of 
APOE. We also tested the model considering a dominant (MAF allele 
carrier vs non-carrier) or recessive (homozygous for the MAF allele 
vs other genotypes) pattern of inheritance for each MAF allele of 
each SNP. Significance was set as p < 0.0018, to correct for multiple 
comparisons with the conservative Bonferroni method. We also 
tested for association of controls, MCI or AD with caffeine SNP, age, 
gender, years of education and APOE genotype with a classification 
and regression tree (CART). These analyses were conducted with the 
aid of the R software version 2.15.2.
Results
Demographic data is summarized in table 2. The MCI group had 
significantly fewer females than control (p = 0.010) or AD (p = 
0.049) groups. AD subjects on average had fewer years of education 
than controls (p = 0.019). There was no difference in APOE alleles 
frequencies between ADNI and AlzGene (table 1, p > 0.90). We ob-
served a strong association of the e4 allele of APOE and AD tested 
with a general linear model controlled by age, gender and education 
compared to healthy controls (p = 2.079 x 10-17). Also, presence of 
APOE e4 in MCI was significantly different from both healthy controls 
(p = 0.0005) and AD patients (p = 4.908 x 10-7). No association was 
observed between the coffee consumption SNPs and AD, for the three 
different scenarios tested (general, dominant MAF allele and recessive 
MAF allele models; table 3). CART analysis showed no association of 
coffee consumption SNPs and the three groups after cross validation. 
However, if we exclude MCI from the analysis, rs6495122 appears as 
Table 1. Coffee consumption SNPs – List of SNPs associated with coffee 
consumption, nearby genes (up to 50 kb, if the SNP is not inside a gene) and 
chromosome they are located – Minor allele frequency (MAF) and p value 
for Hardy-Weinberg equilibrium (HWE; In bold p < 0.10) for each SNP in the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort is also presented
SNP Genes Chr MAF (%) HWE HWE 
Control
HWE
MCI
HWE
AD
rs12148488 PPCDC 15 G (49) 0.275 1.000 0.885 0.033
rs16868941 NCALD 8 A (19) 0.063 - 1.000 0.848
rs2470893 CYP1A1, 
CYP1A2, 
EDC3
15 A (28) 0.179 0.706 0.469 0.144
rs2472297 CYP1A1, 
CYP1A2, 
EDC3, CSK
15 T (21) 0.286 0.622 0.684 0.877
rs2472304 CYP1A2 15 G (37) 0.140 0.140 0.522 0.286
rs382140 LAMB4, 
NRCAM
7 A (17) 0.379 0.507 0.464 0.535
rs4410790 AHR 7 T (41) 0.940 0.659 0.042 0.347
rs5751876 ADORA2A 22 - -
rs6495122 CPLX3, 
ULK3, 
SCAMP2, 
MPI, 
LMAN1L, 
CSK
15 A (45) 0.825 0.774 0.020 0.056
rs762551 CYP1A2 15 C (27) 0.855 0.733 0.698 1.000
Table 2. Summarized demographic data of the ADNI individuals selected 
for this paper and APOE*e4 frequencies for ADNI and AlzGene cohort 
(# p < 0.05 in Fisher exact test when compared to either Healthy control or 
Alzheimer’s Disease groups. * p < 0.05 in ANOVA, with post TUKEY-HSD 
when compared to Healthy control group. & p < 0.05 in Fisher exact test 
when compared to Healthy control)
Healthy control Mild cognitive 
impairment
Alzheimer’s disease
Gender (% 
female)
45.9 33.2# 42.1
Age (mean 
± SD)
79.2 ± 5.5 78.9 ± 6.6 79.3 ± 5.8
Age at 
diagnostics 
(mean ± SD)
- - 75.0 ± 5.9
Years of 
education 
(mean ± SD)
16.0 ± 2.8 15.6 ± 3.2 15.2 ± 3.1*
Handedness  
(% right 
handed)
91.9 94.3 93.7
Ethnic 
background 
(% 
Caucasian)
91.4 90.0 91.8
APOE*e4 (%) 
ADNI
15 25# 42&
AlzGene 14 - 38&
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Figure 1. Coffee consumption SNP (rs6495122) improves the classification 
between healthy controls (1 NL) and Alzheimer's disease patients (3AD) in 
a classification and regression tree. Main factors for classification were 
presence of e4 allele of APOE (E4) and age (PTAGE).
Figure 2. Network of interactions for the corresponding genes whithin 50 kb 
of the selected SNPs. Adapted from image generated with STRING with a 
confidence of 0.5 in June 2013. For better viewing we painted the nodes for 
Alzheimer's disease genes in gray and Coffee consumption in black. Stronger 
interactions are represented with thicker lines. Bigger nodes indicate those 
for which the protein structure has been elucidated.
Table 3. Association of AD and Coffee consumption SNPs in the ADNI cohort – Association of AD and Coffee consumption SNPs in the ADNI cohort was 
evaluated with a multinomial logistic regression model controlled by age, gender, years of education and presence of the e4 allele of APOE followed by Wald 
test – Dominant and Recessive columns, correspond to p value of the model, when testing for dominant (MAF allele carrier vs non-carrier) and recessive 
(homozygous for the MAF allele vs other genotypes) pattern of association. General is the p value with no pattern of inheritance considered. Significance 
was set as p < 0.0018, to correct for multiple comparisons with the conservative Bonferroni method
SNP General
Dominant Recessive
Vs Control AD vs MCI Vs Control AD vs MCI
rs12148488 C: GG(23); GT(50); TT(27)
MCI: GG(26); GT(51); TT(23)
AD: GG(27); GT(44); TT(29)
0.431 -
0.324
0.849
-
0.200
-
0.364
0.218
-
0.779
rs2470893 C: CC(57); CT(36); TT(7)
MCI: CC(51); CT(43); TT(6)
AD: CC(50); CT(39); TT(11)
0.392 -
0.247
0.249
-
0.934
-
0.738
0.330
-
0.166
rs2472297 C: CC(69); CT(28); TT(3)
MCI: CC(60); CT(34); TT(6)
AD: CC(58); CT(36); TT(6)
0.315 -
0.085
0.446
-
0.847
-
0.459
0.624
-
0.733
rs2472304 C: CC(19); CT(43); TT(38)
MCI: CC(11); CT(47); TT(42)
AD: CC(17); CT(44); TT(39)
0.209 -
0.324
0.482
-
0.722
-
0.035
0.752
-
0.052
rs382140 C: CC(65); CT(30); TT(5)
MCI: CC(68); CT(28); TT(4)
AD: CC(71); CT(26); TT(3)
0.741 -
0.559
0.174
-
0.444
-
0.953
0.698
-
0.652
rs4410790 C: AA(17); AG(47); GG(36)
MCI: AA(17); AG(57); GG(26)
AD: AA(17); AG(45); GG(38)
0.049 -
0.011
0.782
-
0.012
-
0.859
0.758
-
0.901
rs6495122 C: GG(31); GT(48); TT(21)
MCI: GG(28); GT(58); TT(14)
AD: GG(32); GT(44); TT(24)
0.024 -
0.629
0.594
-
0.280
-
0.142
0.306
-
0.010
rs762551 C: AA(49); AC(43); CC(8)
MCI: AA(57); AC(38); CC(5)
AD: AA(49); AC(42); CC(9)
0.290 -
0.110
0.618
-
0.211
-
0.386
0.433
-
0.099
a relevant factor to classify between controls and AD (Figure 1). Our 
analysis of protein interactions with STRING revealed no known 
interactions among coffee consumption associated proteins and the 
AD proteins. As can be seen in figure 2 the genes for AD and for coffee 
consumption had no significant interaction (with a confidence greater 
than 0.5 in STRING algorithm). Also, enrichment analysis of KEGG 
pathways showed only a significant (p = 0.038 after FDR correction) 
group of AD associated genes (PSEN1, PSEN2, APP and APOE).
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Discussion
Our results suggest that it is unlikely that the negative association 
between coffee consumption and AD prevalence is due to a common 
genetic background, at least between the regions compared here. We 
found no association between coffee consumption SNPs and AD, also 
there was no correlation between genetic regions and gene products 
for those two characteristics.
Firstly, none of the evaluated coffee consumption SNPs15-17 is ge-
netically near any of the most associated SNPs for AD21. This rule out 
the possibility of linkage disequilibrium between them. Also, there 
was no significant association between coffee consumption SNPs and 
AD in general, dominant MAF allele and recessive MAF allele models 
in the ADNI cohort. Also, rs6495122 appears as a relevant factor for 
classification in CART only after APOE genotype and age, two already 
known risk factors for AD19. Lastly, we found no known interaction 
between the gene products considered for coffee consumption and 
AD, which might have suggested an indirect association. Cornelis 
et al. mentioned in his meta-analysis that the coffee consumption 
SNPs did not showed before in large AD GWAS studies17. This is the 
first attempt to investigate if there is a genetic correlation behind the 
evidence for a protective effect of coffee in AD. Larger cohorts with 
genetic and coffee consumption information might be required to 
further elucidate this question.
Experimental data suggests that caffeine derivates have neurobio-
logical benefits on cognition and AD pathology. It probably results 
from the effects of these substances on signalling pathways related 
to AD pathophysiology and/or neuronal resilience.
Animal models suggested that caffeine administration was associ-
ated with reduction of both soluble and deposited amyloid-β (Aβ) in 
brain7. The hydrophobic nature of caffeine allows its rapid absorption 
through all biological membranes, rendering it is rapidly absorbed 
into the bloodstream and through the blood-brain barrier23. In vitro 
studies, showed that caffeine increases basal synaptic transmission, 
but does not affect LTP, at the same synapses24. However, the concen-
trations of caffeine required to exert these effects, are several orders 
of magnitude higher than the plasmatic concentration attained by 
ingestion of moderate amounts of coffee17,25,26. The only pharmaco-
logical mechanism known for caffeine in the low micromolar range 
is the antagonism of adenosine receptors, namely adenosine A1 and 
A2A receptors and maybe adenosine A3 receptors13,16,27,28, leading 
to many downstream changes, including alterations in gene expres-
sion. The blockade of adenosine receptors confers neuroprotection 
against Aβ6, but the underlying mechanisms by which caffeine 
reduces the relative risk for AD are not well elucidated. Adenosine 
A1 receptors in the cerebral cortex and hippocampus are primarily 
located on pre-synaptic terminals. Caffeine can block those recep-
tors in cholinergic terminals which increases extracellular levels of 
acetylcholine, an important neurotransmitter for cognitive process-
ing, dramatically decreased in the AD brain9. Another plausible 
hypothesis which could explain the decreasing level of Aβ is based 
on enhanced clearance of Aβ from the brain due to upregulation 
of P-glycoprotein (P-gp) induced by caffeine8. P-gp is an adenosine 
triphosphate (ATP) dependent transporter protein, which acts as an 
efflux pump. This transporter is located mainly in luminal membrane 
of brain capillary endothelium comprising the blood-brain-barrier, 
and is responsible for extrusion of drugs and toxins from the brain, 
including Aβ29. An increasing number of studies further suggest that 
alterations in expression and functional activity of P-gp contribute 
to the accumulation of Aβ in the brain, and lead to increased risk 
for developing AD30. A third possible mechanism by which caffeine 
could ameliorate AD prognosis is by acting in neuronal plasticity 
and survival. Caffeine induced both elongation of existing dendritic 
spines and new spine formation in primary cultured hippocampal 
neurons11. Also, long-term caffeine treatment in AD transgenic mice 
decreased pro-inflammatory cytokines such as TNFα and IFNγ in the 
brain10. Taken together with its beneficial effects on signal transduc-
tion12, these results suggest an important role for caffeine in neuronal 
plasticity and survival. There are also other hypotheses about the 
mechanisms involved in neuroprotection by caffeine31, however the 
exactly mechanisms are not completely understood8.
There is no specific information of coffee consumption in the 
ADNI database. This is a limitation of the present analysis, since the 
evaluated SNPs might not correspond directly to coffee consumption 
in this sample. Also, we cannot rule out that the lack of significance 
might be due to a lack of power, because of the sample size. On the 
other hand, the ADNI sample had frequencies of APOE allele similar 
to the general population and we also replicated the strong associa-
tion between APOE e4 allele and AD. These results indicate there 
were no sampling errors.
If we consider a less conservative threshold of p < 0.05, there 
are some observable differences in the MCI group compared to AD 
and/or healthy controls, rs4410790 (general and dominant models), 
rs6495122 (general and recessive models) and rs2472304 (recessive 
model). As mentioned, rs6495122 also appears as a relevant factor 
for the CART. Interestingly, the daily dose associated with cogni-
tive protection is 3 to 5 cups of coffee. Depending on preparation 
and coffee type this dose corresponds to 210-1,100 mg of caffeine 
per day5. In comparison, the coffee consumption SNPs are associ-
ated with a change of less than 1 mg/day in a general model, but a 
maximum 44 mg per day difference between genotypes17. Given the 
effects magnitude, these coffee consumption genetic variants may 
not be a determinant factor in the estimated protective coffee dose. 
However, they might act as outcome modifiers as a result of the di-
rect and indirect interaction with other genetic and environmental 
factors. Thus, it might be a good approach to introduce those SNPs 
as covariables in future studies of coffee and caffeine consumption, 
cognitive deficit and AD.
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